NEW YORK, NY–(Marketwire – April 11, 2011) – It is estimated that at least two million children die each year from diseases that could have been prevented by already existing vaccines. More than 1.2 million of these deaths, 90% of which occur in the developing world, are a result of pneumococcal diseases, according to the WHO. Pneumococcal conjugate vaccines (PCV) are taking aim at these diseases and healthcare market research publisher Kalorama Information estimates in its new report, “Asian Vaccine Markets,” that PCV revenue in Asia grew 18.1% annually since 2006 to reach $442 million in 2010.
“Pneumococcus is a leading cause of serious illness worldwide, and is the most frequent cause of pneumonia, blood infections, sinusitis, and middle ear infections,” said Bruce Carlson, publisher of Kalorama Information. “Although all age groups may be affected, the highest rate of pneumococcal disease occurs in young children and the elderly.”
In early 2010, the United Nations unveiled an action plan designed to save the lives of 10 million women and children over the next five years. Part of the UN’s Millennium Development Goals, the plan calls for increased coverage of three important pediatric vaccines: PCV, rotavirus vaccine, and Haemophilus influenzae type b (Hib) vaccine. It is supported in part by the Bill and Melinda Gates Foundation, which committed $1.5 billion in funding. The initiative is expected to support continued growth of these vaccines.